A detailed history of Victory Capital Management Inc transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 21,195 shares of NUVB stock, worth $49,596. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,195
Previous 18,846 12.46%
Holding current value
$49,596
Previous $68,000 10.29%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$2.58 - $3.69 $6,060 - $8,667
2,349 Added 12.46%
21,195 $61,000
Q1 2024

May 03, 2024

SELL
$1.46 - $3.97 $770 - $2,096
-528 Reduced 2.73%
18,846 $68,000
Q4 2023

Feb 05, 2024

BUY
$0.96 - $1.53 $3,354 - $5,345
3,494 Added 22.0%
19,374 $29,000
Q3 2023

Nov 06, 2023

BUY
$1.26 - $2.1 $514 - $856
408 Added 2.64%
15,880 $21,000
Q2 2023

Jul 27, 2023

SELL
$1.56 - $1.84 $563 - $664
-361 Reduced 2.28%
15,472 $27,000
Q1 2023

May 02, 2023

BUY
$1.6 - $2.48 $480 - $744
300 Added 1.93%
15,833 $26,000
Q4 2022

Feb 09, 2023

SELL
$1.68 - $2.5 $11 - $17
-7 Reduced 0.05%
15,533 $29,000
Q3 2022

Nov 02, 2022

BUY
$0.29 - $4.04 $4,506 - $62,781
15,540 New
15,540 $35,000
Q1 2022

May 04, 2022

SELL
$4.6 - $8.83 $824,526 - $1.58 Million
-179,245 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$7.75 - $10.05 $169,415 - $219,693
-21,860 Reduced 10.87%
179,245 $1.52 Million
Q3 2021

Nov 02, 2021

SELL
$7.78 - $10.0 $12,292 - $15,800
-1,580 Reduced 0.78%
201,105 $2 Million
Q1 2021

May 04, 2021

BUY
$9.0 - $14.57 $1.82 Million - $2.95 Million
202,685 New
202,685 $2.12 Million

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.